Seeking Alpha

Mike Havrilla's  Instablog

Mike Havrilla is an index developer, pharmacist, writer, and Co-Founder of BioMedReports.com with experience that includes online investing since August 1997 and writing for investors since April 2007 with a focus on the healthcare sector and small / micro-cap stocks. Mike holds Doctor of... More
My business:
ProActive HavRx BioFund
My blog:
BioMedReports.com FDA Calendar
My book:
ProActive HavRx Stock Indexes
  • FDA Calendar Updates: Transdel, Javelin, Jazz , Par Pharma 2 comments
    Jun 15, 2009 10:38 AM | about stocks: JAZZ, JAV, UCBJF.PK, PRX

    Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage pivotal Phase 3 clinical trial results which are designed to support a filing for FDA approval.

     
    Transdel Pharma (OTC:TDLP): On 6/15/09, TDLP.OB announced that the Company anticipates reporting top-line results from their current Phase 3 study of Ketotransdel during 3Q09. The Phase 3 study consists of a randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of Ketotransdel, a topical cream based non-steroidal anti-inflammatory drug (NSAID), in acute soft tissue injuries of the upper and lower extremities. The multi-center trial is being conducted at approximately 30 sites in the U.S. and will enroll about 350 patients. TDLP plans to initially seek FDA approval of Ketotransdel for the treatment of acute pain and then expand the label to include additional indications such as osteoarthritis. The Company also stated that it is either engaged in or pursuing discussions with U.S. and foreign based potential partners with sales and marketing infrastructures to support Ketotransdel in the event that the product is approved and commercialized.
     
    Javelin Pharma (AMEX:JAV): On 6/15/09, JAV reported results from a new Phase 1 pharmacokinetic and safety study of Dyloject in patients with mild to moderate renal (kidney) and mild hepatic (liver) impairment. Dyloject was well tolerated in these higher risk patient populations. The elimination rate of Dyloject's active ingredient diclofenac was statistically indistinguishable in all three patient groups compared with matched healthy controls. The Company plans to file a NDA for Dyloject with the FDA for U.S. marketing approval during the fall of 2009 at the same dose used in these studies. Dyloject is an injectable formulation of diclofenac in Phase 3 clinical development in the U.S. and already marketed in the U.K. In December 2008, JAV released top-line results from its second of two Dyloject pivotal Phase 3 clinical trials, which demonstrated effectiveness across all five primary study endpoints.
     
    Jazz Pharma (NASDAQ:JAZZ): On 6/15/09, JAZZ announced that sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase 3 data presented last week. JAZZ has also completed its second Phase 3 clinical trial of JZP-6 and expects to announce top-line results from this study around mid-2009. Assuming positive results for the second study, the company anticipates submitting a NDA for sodium oxybate for the treatment of fibromyalgia to the FDA by the end of 2009. UCB SA (EBR:UCB) (PINK:UCBJF) anticipates filing in the EU shortly after. UCBJF.PK has the exclusive marketing and distribution rights to sodium oxybate for fibromyalgia in Europe and some other countries outside North America and will manage registrations accordingly.
     
    On 6/15/09, BioAlliance Pharma (EPA:BIO) announced the submission of its New Drug Application (NDA) to the FDA for the approval of Loramyc (miconazole) Mucoadhesive Buccal Tablets, developed for the treatment of OroPharyngeal Candidiasis (better known as thrush). If approved, Strativa Pharma, the specialty pharma division of Par Pharma (NYSE: PRX) (which is BioAlliance Pharma’s partner for commercialization in the U.S.) could launch Loramyc in the second half of 2010.
     
    Disclosure: No positions.

     

    Stocks: JAZZ, JAV, UCBJF.PK, PRX
Back To Mike Havrilla's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

This post has 2 comments:

  •  
    Hi Mike,

    Keep up the good work. I look for stocks that have a good potential for 3x-4x gains in a years time. I invest alot in pharmaceutical companies. Its nice to have you researching stocks and keeping us informed of new developments. I already have 2 investments from your articles. Thanks alot.

    sincerely,
    Roy Manning
    Jun 15 09:06 PM | Link | Reply
  •  
    Thanks, Roy -- I hope the two investments from my articles do even better for you than 3-4X returns! Mike


    On Jun 15 09:06 PM Roy Manning wrote:

    > Hi Mike,
    >
    > Keep up the good work. I look for stocks that have a good potential
    > for 3x-4x gains in a years time. I invest alot in pharmaceutical
    > companies. Its nice to have you researching stocks and keeping us
    > informed of new developments. I already have 2 investments from your
    > articles. Thanks alot.
    >
    > sincerely,
    > Roy Manning
    Jun 15 09:39 PM | Link | Reply
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Ticker
AAPL, ABII, ABIO, ABT, ABV, ACAD, ACCP.OB, ACOR, ACUR, ACUS, ADAM, ADLS, AET, AEZS, AFFY, AGEN, AGN, ALKS, ALNY, ALPMF.PK, ALTH, ALXA, AMAG, AMGN, AMLN, AMRN, ANPI, APPA, APPY, ARDM.OB, ARKTF.PK, ARNA, ARUXF.PK, ARYX, ATHN, AUXL, AVNR, AZN, BAX, BAYRY.PK, BCRX, BDSI, BFRM, BIIB, BIOD, BMRN, BMTI, BMY, BPAX, BSX,

Latest Comments


Most Commented
  1. BioMedReports.com Mention in BusinessWeek (7 Comments)
  2. Sequenom Splattered, EXACT Sciences on the Rise (3 Comments)
  3. Who Will Take GM's Place in the Dow? (3 Comments)
  4. 13 Extreme FDA Trades: BioMedReports.com 6/1/09 Update (3 Comments)
  5. Mentor Capital: A Stealth Cancer Immunotherapy Play (3 Comments)
Posts by Themes
allos therapeutics, ANDA, ASCO, Avastin, BIO.PA, BioAlliance, biogenerics, biomed, BioMedReports.com, biotech, BLA, Botox, cancer, cancer biotech, cancer stock, China, cholesterol, Clean Energy, Clinical Trial, Clinical Trial Calendar, Clinical Trials, clinical trials, consumer staples, Crestor, DAVANAT, defensive, Dendreon, Diabetes, Discovery Labs, dividends, Dolphin Secure, Dysport, Enablex, ETF Innovators, Extreme Trades, Facebook, FDA, fda, FDA Calendar, Feraheme, Genentech, generic, Generic Drugs, Global Pharma, GTx, Health IT, Health IT Index, healthcare, Impax Labs, Impax Pharma,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.